Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BTAI Bioxcel Therapeutics Inc.

退市 09-11 16:00:00 EDT

0.0739

+0.0000

0.00%

最高0.0739	最低0.0739	成交量0.00
今开0.0739	昨收0.0739	日振幅0.00%
总市值231.35万	流通市值198.71万	总股本3,131万
成交额0.00	换手率0.00%	流通股本2,689万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BTAI","market":"US","secType":"STK","nameCN":"Bioxcel Therapeutics Inc.","latestPrice":0.0739,"timestamp":1789156800000,"preClose":0.0739,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":26889300,"shares":31305499,"eps":-3.150527,"marketStatus":"退市","change":0,"latestTime":"09-11 16:00:00 EDT","open":0.0739,"high":0.0739,"low":0.0739,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.150527,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1520485200000,"exchange":"NASDAQ","adjPreClose":0.0739,"volumeRatio":0},"requestUrl":"/m/hq/s/BTAI","defaultTab":"news","newsList":[{"id":"1127368326","title":"BioXcel Therapeutics：法院于2026年8月31日下达临时命令，预计2026年9月1日完成首笔950万美元提款及2975万美元债务滚动（SEC文件披露）","url":"https://stock-news.laohu8.com/highlight/detail?id=1127368326","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127368326?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:09","pubTimestamp":1788260940,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics在最新提交给美国证券交易委员会（SEC）的文件中披露，一项临时命令已于2026年8月31日正式生效。根据该命令，公司预计将在2026年9月1日执行首笔950万美元的提款操作，同时推进一项总额达2975万美元的债务滚动安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BTAIQ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104915211","title":"BioXcel Therapeutics与橡树资本及卡塔尔投资局达成DIP信贷协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1104915211","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104915211?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:08","pubTimestamp":1788260927,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics公司宣布，已与橡树资本及卡塔尔投资局正式签署了一项债务人持有资产信贷协议。该消息源自公司向美国证券交易委员会提交的最新文件。根据协议条款，BioXcel Therapeutics将获得来自这两家全球知名投资机构的资金支持，以维持其运营流动性和推进核心业务发展。从行业视角来看，DIP融资通常被视为企业应对财务挑战、寻求重整的重要工具。BioXcel Therapeutics此举能否有效缓解其资金压力并重新聚焦研发管线，市场将拭目以待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAIQ","BTAI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1199782519","title":"BioXcel Therapeutics提交SEC文件：DIP贷款方拟提供最高7725万美元的破产融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1199782519","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199782519?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:05","pubTimestamp":1788260714,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics通过一份提交至美国证券交易委员会的文件披露，DIP贷款方计划为公司提供高至7725万美元的破产重整人持有资产融资。值得关注的是，这笔资金对于正处破产保护进程中的BioXcel Therapeutics而言，可能构成其能否持续运转的关键资金来源。上述信息均源自BioXcel Therapeutics对外披露的SEC申报材料。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BTAIQ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101151484","title":"BioXcel Therapeutics与Teva达成合作：现金5,750万美元，开发里程碑最高可达6,750万美元，商业里程碑2,000万美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1101151484","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101151484?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:11","pubTimestamp":1787911871,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics与Teva签署的合作协议涉及一系列财务安排。根据美国证券交易委员会（SEC）的文件显示，这笔交易包含5,750万美元的现金支付。与此同时，开发里程碑款项最高可达6,750万美元，商业里程碑款项则为2,000万美元。这些条款共同构成了双方合作的基础框架。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108091930","title":"BioXcel Therapeutics破产申请披露：预计负债1亿至5亿美元，资产仅1000万至5000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108091930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108091930?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:40","pubTimestamp":1787881220,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics在法庭文件中披露了其财务状况。这家生物制药公司估计，负债规模在1亿美元至5亿美元之间，而资产价值则徘徊在1000万至5000万美元区间。\n根据法院备案文件显示，该公司的财务困境已浮出水面。负债与资产之间的巨大落差，勾勒出一幅鲜明的财务失衡图景——资产端相对薄弱，负债端却颇为沉重。\n值得关注的是，这一数据区间跨度较大，反映出公司在估值和债务确认方面仍存在不确定性。BioXcel Therapeutics正面临严峻的财务挑战，其资本结构已明显失衡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188330501","title":"BioXcel Therapeutics获贷方新增125万美元贷款，依据第14号修正案定期贷款条款——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1188330501","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188330501?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:20","pubTimestamp":1787656803,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics宣布，根据第14号修正案项下的定期贷款安排，贷方已额外提供125万美元贷款。这一信息源自公司向美国证券交易委员会提交的公开文件。BioXcel Therapeutics近年来持续通过贷款修正案的方式，逐步扩充其财务缓冲空间。SEC文件并未透露这笔新增贷款的更多细节，如利率水平或还款期限等。市场或将密切关注BioXcel Therapeutics后续的财务报告，以评估这笔资金的实际用途及其对公司在研管线推进的支撑作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133277972","title":"BioXcel Therapeutics签署信贷协议第十四次修订案——2026年8月24日SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1133277972","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133277972?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:19","pubTimestamp":1787656750,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics于2026年8月24日正式签署了信贷协议的第十四次修订案。这一动态已通过美国证券交易委员会的官方文件向外界披露。据悉，该公司此次修订动作聚焦于现有信贷安排的条款调整。尽管文件未详细披露修订的具体财务细节，但此举通常意味着融资条件的重新协商或借贷额度的变更。截至目前，BioXcel Therapeutics尚未就此次修订发布额外评论。投资者正密切关注这一融资结构变动对公司运营资金链的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134489117","title":"BioXcel Therapeutics于2026年8月21日签署信贷协议第十三次修订案——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1134489117","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134489117?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:03","pubTimestamp":1787569390,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics——这家生物制药企业于2026年8月21日正式签署了信贷协议的第十三次修订案，相关细节已通过美国证券交易委员会（SEC）的公开文件对外披露。这一动态标志着公司在融资安排上的又一重要调整节点，反映出其持续优化资本结构的战略意图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123597507","title":"BioXcel Therapeutics 必须在2026年8月21日前达成协议以偿还债务或寻求替代资本方案——SEC文件揭示","url":"https://stock-news.laohu8.com/highlight/detail?id=1123597507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123597507?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:05","pubTimestamp":1786446358,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics 面临紧迫的财务时间节点。根据其向美国证券交易委员会提交的文件，该公司被要求在2026年8月21日之前，必须签署相关协议，用以偿还现有债务义务，或者积极寻求替代性的资本解决方案。这一时间限制为其财务状况蒙上了更为严峻的阴影，迫使管理层在有限窗口期内做出关键决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101607103","title":"BioXcel Therapeutics 贷款方放宽最低流动性限制：从625万美元降至300万美元——SEC文件显示","url":"https://stock-news.laohu8.com/highlight/detail?id=1101607103","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101607103?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:05","pubTimestamp":1786446326,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics 迎来关键财务调整。根据最新提交的SEC文件，其贷款方已同意将最低流动性契约要求大幅下调。具体而言，这一门槛从原先的625万美元，显著降低至300万美元。\n此举无疑为该公司提供了更灵活的财务缓冲。在生物科技领域，现金流一直是悬在企业头顶的达摩克利斯之剑。此次契约条件的放宽，意味着BioXcel Therapeutics在短期内面临的资金链压力有所缓解。它可能在当前阶段获得更多战略调整空间，以应对研发支出或市场波动。\n监管文件明确披露了这一变动。对于密切关注该公司股票表现及未来发展路径的投资者而言，这无疑是一个重要的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117292485","title":"Bioxcel Therapeutics：贷款方同意将本金还款推迟至2026年8月31日；根据SEC文件，到期应付本息合计902万美元外加应计利息","url":"https://stock-news.laohu8.com/highlight/detail?id=1117292485","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117292485?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:07","pubTimestamp":1785755227,"startTime":"0","endTime":"0","summary":"Bioxcel Therapeutics Inc.迎来关键财务进展。根据最新提交的SEC文件披露，该公司已与贷款方达成协议，将原定到期的本金还款义务推迟至2026年8月31日。这一调整意味着，届时公司需一次性支付约902万美元的本金，同时还需结清这笔债务在此期间产生的全部应计利息。此次延期协议的签署，为Bioxcel Therapeutics提供了宝贵的现金流缓冲空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154078824","title":"BioXcel Therapeutics需在2026年8月10日前达成最终协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1154078824","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154078824?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:04","pubTimestamp":1785755062,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics公司（股票代码：BTAI）在一份提交给美国证券交易委员会（SEC）的文件中明确表示，该公司必须在2026年8月10日之前签署并落实最终协议。这一时间节点被写入了监管文件，意味着如果未能如期完成，可能面临相应的合规后果。文件内容同时指出，该要求具有强制性，公司方面已对此作出确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108005693","title":"BioXcel Therapeutics在2026年ASCP年会上公布SERENITY At-Home 3期试验新数据，针对双相情感障碍或精神分裂症相关激越","url":"https://stock-news.laohu8.com/highlight/detail?id=1108005693","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108005693?lang=zh_cn&edition=full","pubTime":"2026-05-28 19:02","pubTimestamp":1779966152,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics Inc. 于2026年美国临床精神药理学会年会上，公布了其SERENITY At-Home 3期临床试验的新数据。该试验旨在评估其疗法对与双相情感障碍或精神分裂症相关的急性激越的疗效与安全性。此次公布的数据进一步揭示了该居家给药方案在控制患者激越症状方面的潜力。这些新发现为BioXcel Therapeutics的核心产品线提供了重要支持，特别是在满足精神健康领域对有效且便捷的急性干预措施的迫切需求方面。公司表示，这些数据将有助于推进该疗法的后续监管沟通与开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161815906","title":"BioXcel Therapeutics Inc：FDA为Igalmi新药申请设定PDUFA目标审评日期为2026年11月14日——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1161815906","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161815906?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:00","pubTimestamp":1775041218,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件披露，BioXcel Therapeutics Inc. 已获得美国食品药品监督管理局（FDA）就其Igalmi新药申请设定的处方药使用者付费法案（PDUFA）目标审评日期。该关键日期定于2026年11月14日，标志着监管机构完成审评的最后期限。\n这一进展为该公司针对Igalmi的审批路径提供了明确的时间表，是药物研发过程中的一个重要监管里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176205883","title":"BioXcel Therapeutics宣布FDA受理Igalmi®居家使用补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176205883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176205883?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:00","pubTimestamp":1775041216,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics Inc. (BTAI) 近日宣布，美国食品药品监督管理局（FDA）已正式受理其旗下药物Igalmi®用于居家环境的补充新药申请（sNDA）。这一进展标志着该药物在拓展临床应用场景方面迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518224141","title":"Bioxcel Therapeutics, Inc.盘中异动 大幅上涨5.34%报3.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224141","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518224141?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:34","pubTimestamp":1741613647,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时34分，Bioxcel Therapeutics, Inc.股票出现异动，股价急速拉升5.34%。截至发稿，该股报3.55美元/股，成交量10.9296万股，换手率3.52%，振幅7.57%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2096.04%、413.43%、64.56%，振幅较大的相关个股有Akero Therapeutics, Inc.、Xencor, Inc.、Seer, Inc.，振幅分别为100.05%、99.13%、98.72%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021340796403690&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021340796403690&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2517165369","title":"Bioxcel Therapeutics, Inc.盘中异动 早盘股价大跌6.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517165369","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517165369?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:33","pubTimestamp":1741271605,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时33分，Bioxcel Therapeutics, Inc.股票出现异动，股价大幅下跌6.23%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.60%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为970.92%、111.73%、51.06%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Virax Biolabs Group Limited，振幅分别为24.20%、13.23%、12.51%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223325989eb49e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223325989eb49e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BTAI","LENZ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2517948552","title":"Bioxcel Therapeutics, Inc.盘中异动 早盘大幅拉升17.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948552?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185045,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分，Bioxcel Therapeutics, Inc.股票出现波动，股价快速上涨17.96%。截至发稿，该股报3.19美元/股，成交量444.527万股，换手率143.31%，振幅0.56%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为310.56%、251.30%、183.65%，振幅较大的相关个股有4D Molecular Therapeutics, Inc.、Plus Therapeutics, Inc.、Zura Bio Limited，振幅分别为8.56%、6.59%、5.61%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223045989d458b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223045989d458b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BTAI","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516734634","title":"Bioxcel Therapeutics, Inc.股价拉升12.49% 市值涨94.14万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516734634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516734634?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012337,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Bioxcel Therapeutics, Inc.股票出现波动，股价大幅拉升12.49%。截至发稿，该股报2.43美元/股，成交量33.3719万股，换手率10.76%，振幅3.34%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.32%、27.19%、22.55%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Cibus, Inc.，振幅分别为21.22%、19.25%、9.55%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223217abe63369&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223217abe63369&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BTAI","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378557","title":"Bioxcel Therapeutics, Inc.股价拉升13.86% 市值涨84.68万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514378557?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753062,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Bioxcel Therapeutics, Inc.股票出现波动，股价快速拉升13.86%。截至发稿，该股报1.97美元/股，成交量1489.61万股，换手率480.24%，振幅1.14%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Anaptysbio, Inc.、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.24%、239.11%、55.69%，振幅较大的相关个股有Trevi Therapeutics, Inc.、Enanta Pharmaceuticals, Inc.、Aardvark Therapeutics, Inc.，振幅分别为7.11%、6.58%、6.22%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223102abe0e9f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223102abe0e9f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioxceltherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.9303},{"period":"3month","weight":-0.9352},{"period":"6month","weight":-0.9504},{"period":"1year","weight":-0.9782},{"period":"ytd","weight":-0.9538}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bioxcel Therapeutics, Inc.于2017年3月29日成为特拉华州公司，为BioXcel的全资附属公司。该公司是一家利用人工智能平台开发神经科学领域变革性药物的生物制药公司。其商业产品IGALMI已获批用于治疗与精神分裂症和双相情感障碍相关的急性激越，其研发管线包括针对阿尔茨海默病激越的候选药物及免疫肿瘤学资产。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.080194},{"month":2,"riseRate":0.75,"avgChangeRate":0.207156},{"month":3,"riseRate":0.25,"avgChangeRate":-0.134633},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.031842},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.027429},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.019292},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.052754},{"month":8,"riseRate":0.222222,"avgChangeRate":0.001919},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.193767},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023255},{"month":11,"riseRate":0.375,"avgChangeRate":0.021118},{"month":12,"riseRate":0.375,"avgChangeRate":0.097907}],"exchange":"NASDAQ","name":"Bioxcel Therapeutics Inc.","nameEN":"Bioxcel Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bioxcel Therapeutics Inc.(BTAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bioxcel Therapeutics Inc.,BTAI,Bioxcel Therapeutics Inc.股票,Bioxcel Therapeutics Inc.股票老虎,Bioxcel Therapeutics Inc.股票老虎国际,Bioxcel Therapeutics Inc.行情,Bioxcel Therapeutics Inc.股票行情,Bioxcel Therapeutics Inc.股价,Bioxcel Therapeutics Inc.股市,Bioxcel Therapeutics Inc.股票价格,Bioxcel Therapeutics Inc.股票交易,Bioxcel Therapeutics Inc.股票购买,Bioxcel Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bioxcel Therapeutics Inc.(BTAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}